Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Therapies Année : 2023

Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines

François Cuenot
  • Fonction : Auteur
Alain Weill
  • Fonction : Auteur
Rosemary M. Dray-Spira

Résumé

During the COVID-19 pandemic, EPI-PHARE, a scientific group in pharmaco-epidemiology created by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French National Health Insurance (Cnam), has reoriented its work program to enlighten health authorities in this health crisis. By exploiting massive and complex data of the French Health Data System (SNDS) from the beginning of the first lockdown in France in March 2020, we were able to publish numerous results on the use, benefits and risks of medicines, on the risk factors of COVID-19 before and after vaccination, and on the benefits and risks of COVID-19 vaccines. Our results were widely taken into account by the French health authorities and allowed them to take informed decision in this pandemic situation in order to ensure the health of the population.
Fichier principal
Vignette du fichier
1-s2.0-S0040595723000197-main.pdf (427.38 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04271268 , version 1 (10-11-2023)

Licence

Identifiants

Citer

Mahmoud Zureik, François Cuenot, Alain Weill, Rosemary M. Dray-Spira. Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines. Therapies, 2023, 78 (5), pp.553-557. ⟨10.1016/j.therap.2022.12.013⟩. ⟨hal-04271268⟩
16 Consultations
11 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More